1
|
Zhou X, Hohman AE, Hsu WH. Current review of isoxazoline ectoparasiticides used in veterinary medicine. J Vet Pharmacol Ther 2021; 45:1-15. [PMID: 33733534 DOI: 10.1111/jvp.12959] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 02/08/2021] [Accepted: 02/08/2021] [Indexed: 01/01/2023]
Abstract
The isoxazolines are a novel class of ectoparasiticides with potent inhibitory activity on glutamate- and gamma-aminobutyric acid-gated chloride channel located in nervous system of invertebrates. In recent years, studies have been performed to evaluate the efficacy and safety of isoxazolines against various types of ectoparasites, including fleas, ticks, and mites. As more single and combined isoxazoline products have been approved by the United States Food and Drug Administration and European Medicines Agency, a more comprehensive understanding of isoxazolines becomes essential for veterinary clinical practitioners. This article provides a complete review of isoxazolines with respect to pharmacodynamics, pharmacokinetics, ectoparasiticidal efficacy, and safety, which will provide veterinarians information to allow them to make the best choice of ectoparasiticide for their clients' specific needs.
Collapse
Affiliation(s)
- Xueying Zhou
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, China Agricultural University, Beijing, China
| | - Alexandra E Hohman
- Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, USA
| | - Walter H Hsu
- Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, USA
| |
Collapse
|
2
|
Helke KL, Meyerholz DK, Beck AP, Burrough ER, Derscheid RJ, Löhr C, McInnes EF, Scudamore CL, Brayton CF. Research Relevant Background Lesions and Conditions: Ferrets, Dogs, Swine, Sheep, and Goats. ILAR J 2021; 62:133-168. [PMID: 33712827 DOI: 10.1093/ilar/ilab005] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 11/17/2020] [Accepted: 01/06/2021] [Indexed: 01/01/2023] Open
Abstract
Animal models provide a valuable tool and resource for biomedical researchers as they investigate biological processes, disease pathogenesis, novel therapies, and toxicologic studies. Interpretation of animal model data requires knowledge not only of the processes/diseases being studied but also awareness of spontaneous conditions and background lesions in the model that can influence or even confound the study results. Species, breed/stock, sex, age, anatomy, physiology, diseases (noninfectious and infectious), and neoplastic processes are model features that can impact the results as well as study interpretation. Here, we review these features in several common laboratory animal species, including ferret, dog (beagle), pig, sheep, and goats.
Collapse
Affiliation(s)
- Kristi L Helke
- Department of Comparative Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
| | - David K Meyerholz
- Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA
| | - Amanda P Beck
- Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Eric R Burrough
- Veterinary Diagnostic and Production Animal Medicine Department, Iowa State University, Ames, Iowa, USA
| | - Rachel J Derscheid
- Veterinary Diagnostic and Production Animal Medicine Department, Iowa State University, Ames, Iowa, USA
| | - Christiane Löhr
- Department of Biomedical Sciences, Oregon State University, Corvallis, Oregon, USA
| | - Elizabeth F McInnes
- Toxicologic Pathology, Toxicology Section, Human Safety at Syngenta, in Jealott's Hill, Bracknell, United Kingdom
| | - Cheryl L Scudamore
- ExePathology, Pathologist at ExePathology, Exmouth, Devon, United Kingdom
| | - Cory F Brayton
- Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| |
Collapse
|
3
|
Evaluation of a topical sarolaner-selamectin combination to control flea populations on naturally infested cats in private residences in West Central Florida. Vet Parasitol 2020; 283:109172. [PMID: 32593057 DOI: 10.1016/j.vetpar.2020.109172] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2020] [Revised: 06/15/2020] [Accepted: 06/16/2020] [Indexed: 11/23/2022]
Abstract
Historic data show that home flea infestations can be managed by treating all animals on the premises with a highly effective flea control product. The use of effective products has also been shown to reduce pruritus and minimize dermatologic lesions in both cats and dogs. Therefore, an in-home study was conducted in West Central Florida USA to evaluate the efficacy of a topically applied selamectin-sarolaner formulation to control fleas in naturally infested cats over a 12-week period. Thirty-seven cats in 21 households were treated once monthly with the selamectin-sarolaner topical solution. In the topical fluralaner treatment (positive control) group, forty-three cats in 20 households were treated once on day 0. A combined total of thirty dogs in both groups were treated once monthly with oral sarolaner. Fleas on cats were counted by flea combing, fleas on dogs were counted using visual area counts and fleas in the indoor premises were assessed using intermittent-light flea traps. Blinded-assessments of feline dermatologic lesions (modified-SCORFAD) were conducted monthly by a boarded-dermatologist and pruritus severity was evaluated by pet owners. Three consecutive monthly treatments of selamectin-sarolaner reduced flea populations on cats by 96.3 % within 7 days and by 100% from week 6 to the end of the 12-week study. The topical application of fluralaner reduced flea populations by 98.1 % within 7 days and efficacy reached 100% by week 12. At the end of the study, fleas were completely eradicated (from cats, dogs and homes) in every home regardless of treatment group. Owner reported cat pruritus was reduced by > 87 % in both treatment groups by week 12. Significant improvements in dermatologic lesion scores (> 81 %) were achieved by both products by the end of the study. Monthly applications of topical selamectin-sarolaner or topical fluralaner to cats living in the heavy flea challenge environment of West Central Florida USA were effective in eradicating flea infestations, reducing pruritus and improving dermatologic lesions.
Collapse
|
4
|
Kryda K, Six RH, Walsh KF, Holzmer SJ, Chapin S, Mahabir SP, Myers M, Inskeep T, Rugg J, Cundiff B, Pullins A, Ulrich M, McCall JW, McTier TL, Maeder SJ. Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs. Parasit Vectors 2019; 12:445. [PMID: 31506094 PMCID: PMC6737634 DOI: 10.1186/s13071-019-3702-6] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Accepted: 09/04/2019] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Dirofilaria immitis is a filarial parasite of dogs that can cause serious or fatal cardiopulmonary disease. Three studies were conducted to evaluate the efficacy and safety of monthly treatment with moxidectin in a chewable tablet product in combination with sarolaner and pyrantel to prevent heartworm disease in dogs after experimental challenge and in a clinical field study in the USA. METHODS In two laboratory studies, dogs (8 per group) that had been inoculated 30 days prior with 50 third-stage D. immitis larvae were randomized to treatment on Day 0 with placebo or combination product, at the minimum dose of 24 µg/kg moxidectin, 2 mg/kg sarolaner and 5 mg/kg pyrantel (as pamoate salt). Study 2 also included groups treated with tablets containing moxidectin-alone (24 µg/kg) or sarolaner-alone (2 mg/kg). Efficacy was evaluated ~ 5 months after inoculation by adult heartworm counts at necropsy. In the field study, 410 dogs ≥ 8 weeks-old from 23 USA veterinary clinics were treated for 11 months with either combination product at 24-48 µg/kg moxidectin, 2-4 mg/kg sarolaner and 5-10 mg/kg pyrantel (n = 272) or Heartgard® Plus (ivermectin/pyrantel) at the label recommended dose rate (n = 138). Efficacy was evaluated on Day 330 using antigen and microfilaria testing to assess adult heartworm infection. RESULTS In the laboratory studies, there were no heartworms recovered from any dog treated with the combination product or moxidectin alone and all dogs treated with placebo or sarolaner-alone were infected with 20-44 adult heartworms. In the field study, all dogs treated with the combination product tested negative for heartworm infection on Day 330, whereas two dogs treated with Heartgard® Plus tested positive. The Heartgard® Plus-treated dogs that tested heartworm positive were from the lower Mississippi River Valley region, where heartworm resistance has been confirmed to occur. The combination product was well tolerated in all studies. CONCLUSIONS In laboratory studies, no heartworms were recovered from dogs treated with a single dose of the novel combination product containing moxidectin, sarolaner and pyrantel. Additionally, in the field study no dog tested positive for adult heartworm infection when dosed with the combination product monthly for 11 months, while two dogs treated with Heartgard® Plus tested positive.
Collapse
Affiliation(s)
- Kristina Kryda
- Veterinary Medicine Research and Development, Zoetis, Inc., 333 Portage St, Kalamazoo, MI 49007 USA
| | - Robert H. Six
- Veterinary Medicine Research and Development, Zoetis, Inc., 333 Portage St, Kalamazoo, MI 49007 USA
| | - Kelly F. Walsh
- Veterinary Medicine Research and Development, Zoetis, Inc., 333 Portage St, Kalamazoo, MI 49007 USA
| | - Susan J. Holzmer
- Veterinary Medicine Research and Development, Zoetis, Inc., 333 Portage St, Kalamazoo, MI 49007 USA
| | - Sara Chapin
- Veterinary Medicine Research and Development, Zoetis, Inc., 333 Portage St, Kalamazoo, MI 49007 USA
| | - Sean P. Mahabir
- Veterinary Medicine Research and Development, Zoetis, Inc., 333 Portage St, Kalamazoo, MI 49007 USA
| | - Melanie Myers
- Veterinary Medicine Research and Development, Zoetis, Inc., 333 Portage St, Kalamazoo, MI 49007 USA
| | - Tammy Inskeep
- Veterinary Medicine Research and Development, Zoetis, Inc., 333 Portage St, Kalamazoo, MI 49007 USA
| | - Jady Rugg
- Veterinary Medicine Research and Development, Zoetis, Inc., 333 Portage St, Kalamazoo, MI 49007 USA
| | - Blair Cundiff
- Veterinary Medicine Research and Development, Zoetis, Inc., 333 Portage St, Kalamazoo, MI 49007 USA
| | - Aleah Pullins
- Veterinary Medicine Research and Development, Zoetis, Inc., 333 Portage St, Kalamazoo, MI 49007 USA
| | - Michael Ulrich
- Cheri-Hill Kennel and Supply Inc., 17190 Polk Road, Stanwood, MI 49346 USA
| | | | - Tom L. McTier
- Veterinary Medicine Research and Development, Zoetis, Inc., 333 Portage St, Kalamazoo, MI 49007 USA
| | - Steven J. Maeder
- Veterinary Medicine Research and Development, Zoetis, Inc., 333 Portage St, Kalamazoo, MI 49007 USA
| |
Collapse
|
5
|
Fourie JJ, Liebenberg JE, Crafford D, Six R. Immediate and persistent efficacy of sarolaner (Simparica™) against Haemaphysalis elliptica on dogs. Parasit Vectors 2019; 12:431. [PMID: 31488194 PMCID: PMC6728933 DOI: 10.1186/s13071-019-3696-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Accepted: 08/31/2019] [Indexed: 12/04/2022] Open
Abstract
Background The southern African yellow dog tick, Haemaphysalis elliptica, occurs in eastern and southern Africa and adults infest domestic and wild carnivores. This tick species is also a vector of the highly virulent Babesia rossi pathogen, the causative agent of canine babesiosis in sub-Saharan Africa. Sustained high levels of efficacy of a parasiticide are not only important in protecting dogs against the direct effects of tick infestation, but also in reducing the risk of tick-borne diseases. Sarolaner (Simparica™ chewable tablets) has been reported to be effective against the major tick species infesting dogs in Europe and the USA, including representatives from the genera Amblyomma, Ixodes, Rhipicephalus and Dermacentor. Until now no efficacy evaluations have been reported against species of the genus Haemaphysalis. The objective of the study was to confirm the efficacy of a single 2 mg sarolaner/kg oral dose of Simparica™ against induced infestations with H. (R.) elliptica, an important parasite of dogs in southern Africa. Methods This blinded, randomised, single centre, placebo controlled efficacy study followed a parallel group design and was conducted on two groups consisting of eight purpose-bred dogs each. Animals were treated orally, once on Day 0, with either a placebo compound (Group 1) or Simparica™ (Group 2). Simparica™ was administered orally at a dose rate of 2 mg sarolaner/kg body weight. The dogs were infested with ticks on Days − 7, − 2, 5, 12, 19, 26 and 33, with removal counts conducted on Days − 5, 2, 7, 14, 21, 28 and 35. Results A single oral administration of Simparica™ (sarolaner) at a minimum dose of 2 mg/kg resulted in a 100% efficacy against existing infestations of H. (R.) elliptica on dogs and a 100% reduction in live ticks following weekly re-infestations for 35 days. Moreover, the immediate and persistent high levels of efficacy observed in this study for 35 days is consistent with those observed in previous studies against ticks in other genera. Conclusions The efficacy of sarolaner (Simparica™), administered orally to dogs at the minimum label dose of 2.0 mg/kg, was demonstrated against existing and weekly re-infestations of H. (R.) elliptica for at least 5 weeks. Efficacy of 100% was achieved against existing infestations as well as weekly re-infestations.
Collapse
Affiliation(s)
- Josephus J Fourie
- Clinvet International (Pty) Ltd, Uitzich Road, Bainsvlei, Bloemfontein, South Africa.
| | - Julian E Liebenberg
- Clinvet International (Pty) Ltd, Uitzich Road, Bainsvlei, Bloemfontein, South Africa
| | - Dionne Crafford
- Clinvet International (Pty) Ltd, Uitzich Road, Bainsvlei, Bloemfontein, South Africa.,Zoology Department, University of Johannesburg, Corner of Kingsway and University Roads, Aucklandpark, South Africa
| | - Robert Six
- Zoetis Inc., 333 Portage Street, Kalamazoo, Michigan, 49007, USA
| |
Collapse
|
6
|
Efficacy of three consecutive monthly doses of a topical formulation of selamectin and sarolaner (Revolution ® Plus/Stronghold ® Plus) compared with a single dose of fluralaner (Bravecto ® for Cats) against induced infestations of Ctenocephalides felis on cats. Vet Parasitol 2019; 270 Suppl 1:S52-S57. [PMID: 31133494 DOI: 10.1016/j.vetpar.2019.05.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2019] [Revised: 05/14/2019] [Accepted: 05/15/2019] [Indexed: 11/21/2022]
Abstract
In a controlled laboratory study, the efficacy against fleas, Ctenocephalides felis, of a single treatment of fluralaner topical solution (Bravecto® for Cats, Merck) was compared with that of three consecutive monthly topical treatments with selamectin and sarolaner (Revolution® Plus, Zoetis). Twenty-four domestic short hair cats were ranked based on host suitability flea counts to form groups of three and were randomly assigned within group to one of three treatments. The first group received a topical treatment with (a) placebo (vehicle control for Revolution® Plus) on Days 0, 30, and 60, (b) 6 mg/kg selamectin and 1 mg/kg sarolaner on Days 0, 30, and 60, or (c) 40 mg/kg fluralaner on Day 0 and placebo (vehicle control for Revolution® Plus) on Days 30 and 60. Because doses were rounded off, the selamectin plus sarolaner-treated cats received effective dosages of 5.25-6.60 mg/kg selamectin and 0.88-1.10 mg/kg sarolaner, while the fluralaner-treated cats received dosages of 34.71-43.08 mg/kg fluralaner. All cats were infested with 100 (±5) fleas on Day -1 and at biweekly intervals after that, from Day 13 to Day 89. Flea comb counts were conducted 24 hours after treatment or after re-infestation. There were no adverse events related to treatment during the study. Except for a single cat from which 20 fleas were recovered on Day 90, all other placebo-treated cats had at least 48 fleas at each count, indicating adequacy of infestation of the controls. Based on geometric mean live flea counts, three consecutive monthly treatments with Revolution® Plus resulted in consistent and high efficacy of ≥98.6% compared with placebo throughout the study. A single treatment with Bravecto® for Cats provided consistent and high efficacy of ≥94.6% on all count days during a period of 12 weeks, the approved duration of efficacy for the product. Based on the efficacy results of the study, both products were equivalent in their ability to control fleas on cats. Use of Bravecto® for Cats every 12 weeks or the consecutive monthly use of Revolution® Plus is expected to provide extended high residual kill over the respective labeled durations of efficacy of the two products.
Collapse
|
7
|
Dryden MW, Canfield MS, Bocon C, Phan L, Niedfeldt E, Kinnon A, Warcholek SA, Smith V, Bress TS, Smith N, Heaney K, Royal C, Normile D, Armstrong R, Sun F. In-home assessment of either topical fluralaner or topical selamectin for flea control in naturally infested cats in West Central Florida, USA. Parasit Vectors 2018; 11:422. [PMID: 30012222 PMCID: PMC6048752 DOI: 10.1186/s13071-018-2995-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Accepted: 07/05/2018] [Indexed: 11/24/2022] Open
Abstract
Background An investigation was conducted in West Central Florida, USA to evaluate the efficacy of either topically applied fluralaner or topically applied selamectin to control flea infestations, minimize dermatologic lesions and reduce pruritus in naturally flea infested cats over a 12-week period. When dogs were present in the households, they were treated with either oral fluralaner (if household cats were treated with topical fluralaner) or oral sarolaner (if household cats were treated with topical selamectin). Methods Thirty-one cats in 20 homes were treated once with fluralaner topical solution on day 0 and 18 dogs in these homes were administered a single fluralaner chewable. Twenty-nine cats in 18 homes were treated once monthly with a selamectin topical solution for 3 treatments and 13 dogs in these same homes were treated once monthly for 3 treatments with a sarolaner chewable. Fleas on cats were counted by flea combing, fleas on dogs were estimated using visual area counts and fleas in the indoor premises were assessed using intermittent-light flea traps. Blinded-assessments of feline dermatologic lesions were conducted monthly and pruritus severity was evaluated by pet owners. Results A single topical application of fluralaner reduced flea populations on cats by 96.6% within 7 days and by 100% at 12 weeks post-treatment. This efficacy was significantly greater than selamectin treatment where single topical application reduced flea populations on cats by 79.4% within 7 days of initial treatment and 3 consecutive monthly treatments reduced flea populations by 91.3% at the end of 12 weeks. At the end of the 12-week study, all fluralaner-treated cats were flea-free and this was significantly greater than the 38.5% of selamectin treated cats that were flea-free. At the end of the study, fleas were completely eradicated (from cats, dogs and homes) in 95.0% of fluralaner treatment group homes, significantly greater than the 31.3% of selamectin/sarolaner treatment group homes with complete flea eradication. Owner reported cat pruritus was reduced similarly in both treatment groups. Significant improvements in dermatologic lesion scores were achieved by day 30 in fluralaner treated cats and by day 60 in selamectin treated cats. Conclusions An in-home investigation in subtropical Florida found that 1 application of topical fluralaner eliminated flea infestations on cats and in homes significantly more effectively than 3 consecutive monthly doses of selamectin.
Collapse
Affiliation(s)
- Michael W Dryden
- Deptartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
| | - Michael S Canfield
- Animal Dermatology South, 7741 Congress St New Port Richey, Port Richey, FL, 34653, USA
| | - Cara Bocon
- Deptartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA
| | - Letitia Phan
- Deptartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA
| | - Emily Niedfeldt
- Deptartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA
| | - Amanda Kinnon
- Deptartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA
| | - Stanislaw A Warcholek
- Deptartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA
| | - Vicki Smith
- Deptartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA
| | - Todd S Bress
- Animal Dermatology South, 7741 Congress St New Port Richey, Port Richey, FL, 34653, USA
| | - Nicole Smith
- Animal Dermatology South, 7741 Congress St New Port Richey, Port Richey, FL, 34653, USA
| | - Kathleen Heaney
- Merck Animal Health, 2 Giralda Farms, Madison, NJ, 07940, USA
| | - Christine Royal
- Merck Animal Health, 2 Giralda Farms, Madison, NJ, 07940, USA
| | - Dorothy Normile
- Merck Animal Health, 2 Giralda Farms, Madison, NJ, 07940, USA
| | | | - Fangshi Sun
- Merck Animal Health, 2 Giralda Farms, Madison, NJ, 07940, USA
| |
Collapse
|
8
|
Dryden MW, Canfield MS, Niedfeldt E, Kinnon A, Kalosy K, Smith A, Foley KM, Smith V, Bress TS, Smith N, Endrizzi M, Login J. Evaluation of sarolaner and spinosad oral treatments to eliminate fleas, reduce dermatologic lesions and minimize pruritus in naturally infested dogs in west Central Florida, USA. Parasit Vectors 2017; 10:389. [PMID: 28814316 PMCID: PMC5559866 DOI: 10.1186/s13071-017-2328-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Accepted: 08/09/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND An in-home investigation of naturally flea infested dogs was conducted in West Central Florida, USA to evaluate and compare the effectiveness of two different oral flea adulticides to control flea infestations, minimize dermatologic lesions and reduce pruritus over an 8-week period. METHODS Twenty-nine dogs living in 19 homes and another 26 dogs residing in 16 different homes were orally administered either a sarolaner or spinosad chewable, respectively on day 0 and once between days 28-30. Products were administered by study personnel according to label directions. Flea populations on dogs were estimated using visual area counts and flea infestations in the indoor premises were assessed using intermittent-light flea traps on days 0, 7, 14, 21 and once between days 28-30, 40-45, and 56-60. Assessments of dermatologic lesions were conducted monthly during the study and severity of pruritus was evaluated throughout the study on the same schedule as flea counts were conducted. Concurrent treatments for existing skin disease were not allowed. RESULTS The administration of sarolaner or spinosad reduced flea populations on dogs by 99.0% and 97.3%, respectively within 7 days. Flea infestations on the sarolaner- and spinosad-treated dogs were reduced by > 99% at every counting period from day 14 post-treatment through the end of the 8-week study. At the end of the study 96.4 and 92.0% of the dogs treated with sarolaner and spinosad, respectively were flea-free. Flea populations in the indoor premises were also markedly reduced the end of the study, with 100 and 99.8% reductions in flea trap counts in the sarolaner and spinosad treatment groups, respectively. FAD lesion scores, atopic dermatitis lesions scores (CADESI-4) and pruritus severity scores were also markedly improved with both formulations. CONCLUSIONS An in-home clinical field study conducted during the summer of 2016 in subtropical Florida demonstrated that two-monthly administrations of either sarolaner or spinosad chewables almost completely eliminated flea infestations on dogs and in private residences, while markedly reducing dermatology lesions and pruritus.
Collapse
Affiliation(s)
- Michael W. Dryden
- Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS 66506 USA
| | | | - Emily Niedfeldt
- Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS 66506 USA
| | - Amanda Kinnon
- Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS 66506 USA
| | - Kimberly Kalosy
- Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS 66506 USA
| | - Amber Smith
- Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS 66506 USA
| | - Kaitlin M. Foley
- Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS 66506 USA
| | - Vicki Smith
- Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS 66506 USA
| | - Todd S Bress
- Animal Dermatology South, 7741 Congress Str, New Port Richey, FL 34653 USA
| | - Nicole Smith
- Animal Dermatology South, 7741 Congress Str, New Port Richey, FL 34653 USA
| | - Mike Endrizzi
- Zoetis US LLC, 100 Campus Drive, W4668, Florham Park, NJ 07932 USA
| | - Joyce Login
- GBBM Consulting, 16036 Eagle River Way, Tampa, FL 33624 USA
| |
Collapse
|
9
|
Packianathan R, Colgan S, Hodge A, Davis K, Six RH, Maeder S. Efficacy and safety of sarolaner (Simparica ®) in the treatment and control of naturally occurring flea infestations in dogs presented as veterinary patients in Australia. Parasit Vectors 2017; 10:387. [PMID: 28814332 PMCID: PMC5559772 DOI: 10.1186/s13071-017-2321-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Accepted: 08/02/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The efficacy and safety of a novel isoxazoline compound, sarolaner (Simparica®, Zoetis) and spinosad (Comfortis®, Elanco) as a positive control were evaluated for the treatment and control of natural flea infestations on dogs in two randomised, blinded, multi-centric clinical trials conducted in 11 veterinary clinics in northeastern and southeastern states of Australia. METHODS A total of 162 client-owned dogs (80 in northern study and 82 in southern study) from 105 households were enrolled. Each household was randomly allocated to receive either sarolaner (Simparica®, Zoetis) or spinosad (Comfortis®, Elanco). Dogs were dosed on Days 0, 30 and 60 and physical examinations and flea counts were conducted on Days 0, 14, 30, 60 and 90. Efficacy assessments were based on the percentage reduction in live flea counts post-treatment compared to Day 0. RESULTS In the northern study, at enrolment, primary dogs had flea counts ranging from 5 to 772. At the first efficacy assessment on Day 14, sarolaner resulted in 99.3% mean reduction in live flea counts relative to Day 0, compared to 94.6% in the spinosad group. On Day 30, the sarolaner-treated group had mean efficacy of 99.2% compared to 95.7% in the spinosad-treated group, and on days 60 and 90, both groups had mean efficacies of ≥ 98.8%. In the southern study, at enrolment, primary dogs had flea counts ranging from 5 to 156. Both sarolaner and spinosad resulted in ≥ 96.7% mean reduction in live flea counts on Day 14. On Day 30, the sarolaner-treated group had mean efficacy of 99.5% compared to 89.7% in the spinosad-treated group, and on days 60 and 90, both groups had mean efficacies of ≥ 98.6%. No treatment-related adverse events were observed in either study. CONCLUSIONS A single monthly dose of sarolaner (Simparica®) administered orally at 2-4 mg/kg for three consecutive months was well tolerated and provided excellent efficacy against natural infestations of fleas under a range of Australian field conditions including different climatic and housing conditions. Similar efficacy was observed with spinosad (Comfortis®) after the second and third monthly treatments.
Collapse
Affiliation(s)
- Raj Packianathan
- Zoetis, Veterinary Medicine Research and Development, Level 6, 5 Rider Boulevard, Rhodes, NSW, 2138, Australia.
| | - Sally Colgan
- Eurofins SCEC, PO Box 211, Northbridge, NSW, 1560, Australia
| | - Andrew Hodge
- Zoetis, Veterinary Medicine Research and Development, Level 6, 5 Rider Boulevard, Rhodes, NSW, 2138, Australia
| | - Kylie Davis
- Zoetis, Veterinary Medicine Research and Development, Level 6, 5 Rider Boulevard, Rhodes, NSW, 2138, Australia
| | - Robert H Six
- Zoetis, Veterinary Medicine Research and Development, 333 Portage St, Kalamazoo, MI, 49007, USA
| | - Steven Maeder
- Zoetis, Veterinary Medicine Research and Development, 333 Portage St, Kalamazoo, MI, 49007, USA
| |
Collapse
|
10
|
Cvejić D, Schneider C, Neethling W, Hellmann K, Liebenberg J, Navarro C. The sustained speed of kill of ticks ( Rhipicephalus sanguineus ) and fleas ( Ctenocephalides felis felis ) on dogs by a spot-on combination of fipronil and permethrin (Effitix ® ) compared with oral afoxolaner (NexGard ® ). Vet Parasitol 2017; 243:52-57. [DOI: 10.1016/j.vetpar.2017.06.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2016] [Revised: 06/02/2017] [Accepted: 06/09/2017] [Indexed: 12/14/2022]
|
11
|
Vatta AF, Everett WR, Holzmer SJ, Cherni JA, King VL, Rugg D, Geurden T. Efficacy of a new spot-on formulation of selamectin plus sarolaner for cats against adult Ctenocephalides felis, flea egg production and adult flea emergence. Vet Parasitol 2017; 238 Suppl 1:S22-S26. [PMID: 28395752 DOI: 10.1016/j.vetpar.2017.02.026] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 02/20/2017] [Accepted: 02/23/2017] [Indexed: 10/19/2022]
Abstract
A new spot-on formulation of selamectin plus sarolaner was evaluated against fleas for adulticidal efficacy, and for the effect on egg production and hatching when applied to flea-infested cats. Ten male and ten female adult domestic shorthair cats were randomly assigned to one of two treatment groups based on pre-treatment flea counts. Cats received topical treatment on Day 0 in a single spot to the dorsal scapular area with either a placebo formulation or with the combination formulation at the minimal dose of 6.0mg selamectin plus 1.0mg sarolaner per kg bodyweight. On Days -1, 5, 12, 19, 26 and 33, cats were infested with approximately 100 (±5) unfed Ctenocephalides felis fleas. At 24h after treatment or 48h after subsequent flea infestation, cats were housed for a 20-h period in a cage to allow collection of flea eggs. At the end of this period, flea eggs were collected from the cages and cats were combed to remove and count live fleas. Emerged viable larvae and emerged adult fleas were counted 3days and 35days, respectively, after egg collection. The new spot-on formulation of selamectin plus sarolaner provided 100% efficacy against adult fleas up to Day 36 following a single application. Fleas on placebo-treated cats produced large numbers of eggs throughout the study, with individual counts ranging from 110 to 1256 eggs. Following treatment, four flea eggs were collected from a single selamectin/sarolaner-treated cat on Day 29, but there were no eggs collected from any other selamectin/sarolaner-treated animal during the study. No larvae or adult fleas developed from these four eggs. From the eggs collected from the placebo-treated cats, the mean percentage of live larvae and adults that emerged ranged from 67.3% to 84.2% and from 50.7% to 81.8%, respectively. A single topical treatment with a new spot-on formulation of selamectin plus sarolaner at the minimum label dose thus controlled fleas on cats and was 100% effective in preventing flea reproduction for over one month after treatment.
Collapse
Affiliation(s)
- Adriano F Vatta
- Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI 49007, USA.
| | | | - Susan J Holzmer
- Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI 49007, USA
| | - Judith A Cherni
- Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI 49007, USA
| | - Vickie L King
- Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI 49007, USA
| | - Douglas Rugg
- Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI 49007, USA
| | - Thomas Geurden
- Zoetis, Veterinary Medicine Research and Development, Hoge Wei 10, B-1930 Zaventem, Belgium
| |
Collapse
|
12
|
Cherni JA, Mahabir SP, Six RH. Efficacy and safety of sarolaner (Simparica™) against fleas on dogs presented as veterinary patients in the United States. Vet Parasitol 2016; 222:43-8. [DOI: 10.1016/j.vetpar.2015.12.022] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Revised: 12/09/2015] [Accepted: 12/21/2015] [Indexed: 11/16/2022]
|
13
|
Six RH, Becskei C, Carter L, Gale B, Young DR, Mahabir SP, Chapin S, Myers MR. Evaluation of the speed of kill, effects on reproduction, and effectiveness in a simulated infested-home environment of sarolaner (Simparica™) against fleas on dogs. Vet Parasitol 2016; 222:23-7. [PMID: 26961589 DOI: 10.1016/j.vetpar.2016.02.026] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Revised: 02/17/2016] [Accepted: 02/25/2016] [Indexed: 12/01/2022]
Abstract
Four studies were conducted to evaluate the speed of kill, effect on egg production, and efficacy in a simulated infested-home environment of a novel isoxazoline, sarolaner (Simparica™, Zoetis), against fleas on dogs. Individually identified and housed, purpose-bred Beagles were used in each study and were allocated randomly to groups based on pretreatment parasite counts. In two speed of kill studies, groups of dogs infested with 100 fleas prior to treatment were treated orally with placebo or sarolaner tablets providing the minimum dose of 2mg/kg and then re-infested with fleas weekly for five weeks post-treatment. Comb counts were conducted to determine the numbers of viable fleas at one to three, four, eight and 12h after treatment and each subsequent infestation. In the egg production study, sarolaner- and placebo-treated dogs were similarly challenged with fleas and at 48h after each infestation the dogs were housed for 20h in cages allowing the collection and counting of all flea eggs produced during this period. Collected eggs were incubated to evaluate hatch and development to adults. The last study used dogs housed in a flea-infested simulated-home environment. Dogs were allocated to treatment with either placebo or sarolaner tablets providing a dose of 2mg/kg once a month for three treatments. Flea infestations were assessed by comb counts (fleas were replaced on the dogs) on Days 14, 30, 44, 60, 74 and 90. The speed of kill studies demonstrated that a single 2mg/kg oral dose of sarolaner started killing fleas within three to four hours after treatment or subsequent re-infestations for up to a month, and achieved ≥98% control of fleas by eight hours after treatment or re-infestation for 28 days. In the study to assess effects on flea reproduction, a single oral treatment of sarolaner resulted in the complete cessation of egg-laying for 35 days. This rapid kill of fleas and inhibition of reproduction were confirmed in a simulated-home environment where the existing infestations were reduced by >95% within two weeks of the first treatment and eliminated from the dogs after two monthly doses.
Collapse
Affiliation(s)
- Robert H Six
- Zoetis, Veterinary Medicine Research and Development, 333 Portage St., Kalamazoo, MI 49007, USA.
| | - Csilla Becskei
- Zoetis, Veterinary Medicine Research and Development, Hoge Wei 10, B-1930 Zaventem, Belgium
| | - Lori Carter
- Stillmeadow Inc., 12852 Park One Drive, Sugar Land, TX 77478, USA
| | - Boyd Gale
- Charles River Laboratories, Pre-Clinical Services, Glenamoy Co., Mayo, Ireland
| | | | - Sean P Mahabir
- Zoetis, Veterinary Medicine Research and Development, 333 Portage St., Kalamazoo, MI 49007, USA
| | - Sara Chapin
- Zoetis, Veterinary Medicine Research and Development, 333 Portage St., Kalamazoo, MI 49007, USA
| | - Melanie R Myers
- Zoetis, Veterinary Medicine Research and Development, 333 Portage St., Kalamazoo, MI 49007, USA
| |
Collapse
|